Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2022

View Archived Issues

NOS targeting to treat ischemic stroke

Serum PRO-C6 monitors and predicts infliximab response in patients with Crohn's disease

New TLR8 agonists identified at National Institute of Pharmaceutical R&D Co.

FLT3 inhibitors discovered at Cytosinlab Therapeutics

Janssen Pharmaceutica presents new factor XIa inhibitors

Roche patents vasopressin V1A receptor antagonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical identify new SOS1 inhibitors

Targeting sphingolipid synthesis has multiple beneficial effects in Duchenne model

SAF-248 shows potent activity against DLBCL in vitro and in vivo

STC-2 administration confers post-stroke functional recovery in a preclinical model

R2M3-26, a novel Wnt mimetic with promising efficacy in mouse model of colitis

3-beta-HSD linked to depression in males due to testosterone degradation

JN Nova advances COVID-19 therapeutic JN-2019 into clinic

T-cell evasion is one pressure shaping SARS-CoV-2 evolution

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.